CCONNECTA Therapeutics — Series A · €3.1M
The Barcelona Science Park biotech raised €3.1M led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth fund, with existing backers Inveready, CDTI Innvierte and Prous Institute. The money completes the Phase IIa trial of CTH120, a TrkB neuroplasticity modulator for Fragile X syndrome, with topline data expected mid-2027.
LeadClave Capital
RoundSeries A
Announced10 Sep 2026
CityBarcelona
SectorHealthtech & Bio · Biotech / CNS therapeutics
Source
G
I
W
E
→
G
I
W
E
→
The company
Investors 4
CClave Capital
clave.capital
CCDTI Innvierte
www.cdti.es
Profile: Centro para el Desarrollo Tecnológico y la Innovación
IInveready
inveready.com
P
Prous Institute for Biomedical Research